Key Takeaways
- The BIOSECURE Act aims to decouple the U.S. biopharmaceutical supply chain from China, limiting federal contracts with designated Chinese biotech firms.
The BIOSECURE Act Overview
On December 18, 2025, President Trump signed the FY2026 National Defense Authorization Act, which includes the BIOSECURE Act aimed at limiting U.S. federal funding to Chinese biotech firms perceived as security risks. While its intent is to safeguard sensitive information and resources, the true impact may be less straightforward due to deep-rooted supply chains linking U.S. companies to Chinese manufacturing and research capabilities.
The BIOSECURE Act does not outright ban American companies from working with Chinese firms; instead, it restricts federal agencies and contractors from procuring services from specified “companies of concern.” This creates significant pressure to comply with federal funding requirements rather than imposing a blanket prohibition on business relationships.
Crucially, the final version of the law does not name specific companies but instead relies on an ongoing list of firms identified as threats under the Defense Department’s Section 1260H. Some entities like BGI and its affiliate MGI are already designated, while others, such as WuXi AppTec, are in limbo. The Office of Management and Budget is tasked with determining which firms will be classified, and these designations could evolve over time.
The law introduces a lengthy timeline for implementation, with prohibitions only coming into effect after the Federal Acquisition Regulation is amended. This has led to industry confusion and a flurry of activity to secure contracts before the rules tighten.
Global Biopharma Dependency on China
Dependencies on Chinese firms are stark: nearly 80% of U.S. biotech companies are intertwined with Chinese entities, which have increasingly supplied new compounds for drug development. China’s biopharmaceutical ecosystem is not only cheaper but much faster, making it attractive to Western companies. Since 2020, U.S. firms have engaged in significant licensing deals valued at around $53 billion with Chinese biopharma.
The so-called “China+1” strategy presupposes that work will shift to other countries like India, Korea, and Japan. However, not all countries have the capacity or the right facilities to absorb this displaced volume quickly. While Korea is building capacity for large-molecule biologics rapidly, India excels in small-molecule production but lags in advanced therapies, thus posing a complicated challenge for U.S. firms.
Possible Industry Implications
The BIOSECURE Act could lead to increased production costs and longer timelines for drug development, as firms must navigate the transition away from Chinese suppliers. The act’s grandfathering provisions may offer temporary relief, but the ultimate impact on drug pricing and development pace could be detrimental to American patients.
While BIOSECURE aims to enhance national security, its gradual implementation and complexities in the biopharmaceutical landscape will likely result in significant industry disruptions. As companies assess their supply chains, the long-term repositioning efforts may prove costly and challenging.
The content above is a summary. For more details, see the source article.